{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:29:09Z","timestamp":1780921749627,"version":"3.54.1"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Apremilast, a small molecule that acts by inhibition of the phosphodiesterase-4 enzyme, has been approved by the US Food and Drug Administration for the management of psoriatic arthritis, plaque psoriasis and Beh\u00e7et disease. The drug has drawn much interest from practising dermatologists in view of its exceptional safety profile and prescription convenience, as evident by the recent surge of literature describing its off-label indications. This review was carried out with the aim of summarizing the literature on off-label use of apremilast in dermatology, in order to guide clinicians regarding currently available evidence. The PubMed database was searched using \u2018apremilast\u2019 as a keyword in the title. Abstracts were individually screened to determine whether there was a description of an off-label use of apremilast in dermatology within the article. Randomized controlled trial data were available for vitiligo, alopecia areata, hidradenitis suppurativa and atopic dermatitis. Case series and case reports describing apremilast were also reviewed. Owing to its broad spectrum of immunomodulatory activity, apremilast may be useful in several chronic inflammatory skin diseases recalcitrant to conventional therapies, either alone or in combination with other drugs. Further studies are needed to establish its role in various dermatological indications.<\/jats:p>","DOI":"10.1111\/ced.15377","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T05:45:41Z","timestamp":1660715141000},"page":"2136-2149","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evolving utility of apremilast in dermatological disorders for off-label indications"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7481-2330","authenticated-orcid":false,"given":"Hitaishi","family":"Mehta","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology Postgraduate Institute of Medical Education and Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology Postgraduate Institute of Medical Education and Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-0085","authenticated-orcid":false,"given":"Sunil","family":"Dogra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology Postgraduate Institute of Medical Education and Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"2023010808133853300_ced15377-bib-0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/idoj.IDOJ_437_18","article-title":"Apremilast in psoriasis and beyond: big hopes on a small molecule","volume":"10","author":"Afra","year":"2019","journal-title":"Indian Dermatol Online J"},{"key":"2023010808133853300_ced15377-bib-0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121516","article-title":"Development of an amorphous based sustained release system for apremilast a selective phosphodiesterase 4 (PDE4) inhibitor","volume":"615","author":"Zhang","year":"2022","journal-title":"Int J Pharm"},{"key":"2023010808133853300_ced15377-bib-0003","article-title":"Apremilast is effective in controlling the progression of adult vitiligo: a case series","volume":"32","author":"Majid","year":"2019","journal-title":"Dermatol Ther"},{"key":"2023010808133853300_ced15377-bib-0004","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jid.2019.11.031","article-title":"Apremilast in combination with narrowband UVB in the treatment of vitiligo: a 52-week monocentric prospective randomized placebo-controlled study","volume":"140","author":"Khemis","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2023010808133853300_ced15377-bib-0005","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jaad.2020.12.073","article-title":"Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: a randomized split-body pilot study","volume":"85","author":"Kim","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023010808133853300_ced15377-bib-0006","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13064","article-title":"One stone, two birds: improvement of early-onset vitiligo under apremilast in a patient with plaque psoriasis","volume":"32","author":"Plachouri","year":"2019","journal-title":"Dermatol Ther"},{"key":"2023010808133853300_ced15377-bib-0007","article-title":"Repigmentation of tenacious vitiligo on apremilast","volume":"2017","author":"Huff","year":"2017","journal-title":"Case Rep Dermatol Med"},{"key":"2023010808133853300_ced15377-bib-0008","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1684\/ejd.2019.3576","article-title":"Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata","volume":"29","author":"Sakakibara","year":"2019","journal-title":"Eur J Dermatol"},{"key":"2023010808133853300_ced15377-bib-0009","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/ajd.12934","article-title":"Improvement of alopecia areata with apremilast","volume":"60","author":"Magdaleno-Tapial","year":"2019","journal-title":"Australas J Dermatol"},{"key":"2023010808133853300_ced15377-bib-0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00403-018-1876-y","article-title":"A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata","volume":"311","author":"Mikhaylov","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"2023010808133853300_ced15377-bib-0011","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jaad.2017.05.034","article-title":"Lack of efficacy of apremilast in 9 patients with severe alopecia areata","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023010808133853300_ced15377-bib-0012","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1684\/ejd.2020.3749","article-title":"Apremilast for extensive and treatment-resistant alopecia areata: a retrospective analysis of five patients","volume":"30","author":"Weber","year":"2020","journal-title":"Eur J Dermatol"},{"key":"2023010808133853300_ced15377-bib-0013","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/09546634.2019.1616046","article-title":"Apremilast is efficacious in refractory alopecia areata","volume":"31","author":"Taneja","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2023010808133853300_ced15377-bib-0014","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jid.2018.10.043","article-title":"A phase 2 randomized trial of apremilast in patients with atopic dermatitis","volume":"139","author":"Simpson","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2023010808133853300_ced15377-bib-0015","first-page":"341","article-title":"A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis","volume":"11","author":"Volf","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"2023010808133853300_ced15377-bib-0016","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archdermatol.2012.812","article-title":"A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults","volume":"148","author":"Samrao","year":"2012","journal-title":"Arch Dermatol"},{"key":"2023010808133853300_ced15377-bib-0017","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaad.2017.03.020","article-title":"Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses","volume":"77","author":"Abrouk","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023010808133853300_ced15377-bib-0018","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaad.2017.02.026","article-title":"Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients","volume":"76","author":"Weber","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023010808133853300_ced15377-bib-0019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2023010808133853300_ced15377-bib-0020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/jdv.15354","article-title":"Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers","volume":"33","author":"Vossen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010808133853300_ced15377-bib-0021","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2020.08.113","article-title":"Long-term treatment with apremilast in hidradenitis suppurativa: a 2-year follow-up of initial responders","volume":"85","author":"Aarts","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023010808133853300_ced15377-bib-0022","first-page":"170","article-title":"Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study","volume":"18","author":"Kerdel","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"2023010808133853300_ced15377-bib-0023","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaad.2012.07.014","article-title":"An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series","volume":"68","author":"Paul","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2023010808133853300_ced15377-bib-0024","first-page":"1026","article-title":"Oral lichen planus treated with apremilast","volume":"15","author":"Bettencourt","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"2023010808133853300_ced15377-bib-0025","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000447051","article-title":"Apremilast is effective in lichen planus mucosae-associated stenotic esophagitis","volume":"8","author":"Hafner","year":"2016","journal-title":"Case Rep Dermatol"},{"key":"2023010808133853300_ced15377-bib-0026","first-page":"56","article-title":"Treatment of recalcitrant erosive oral lichen planus and desquamative gingivitis with oral apremilast","volume":"10","author":"AbuHilal","year":"2016","journal-title":"J Dermatol Case Rep"},{"key":"2023010808133853300_ced15377-bib-0027","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaad.2020.05.112","article-title":"Apremilast for the off-label treatment of lichenoid and interface dermatoses","volume":"83","author":"Ravichandran","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023010808133853300_ced15377-bib-0028","first-page":"343","article-title":"Apremilast in oral lichen planus \u2013 a multicentric, retrospective study","volume":"20","author":"Perschy","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"2023010808133853300_ced15377-bib-0029","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/s13063-021-05428-w","article-title":"Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial","volume":"22","author":"Skullerud","year":"2021","journal-title":"Trials"},{"key":"2023010808133853300_ced15377-bib-0030","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamadermatol.2018.2191","article-title":"Treatment of severe Hailey-Hailey disease with apremilast","volume":"154","author":"Kieffer","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2023010808133853300_ced15377-bib-0031","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/1346-8138.16178","article-title":"Two cases of Hailey-Hailey disease effectively treated with apremilast and a review of reported cases","volume":"48","author":"Yoto","year":"2021","journal-title":"J Dermatol"},{"key":"2023010808133853300_ced15377-bib-0032","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/ced.14225","article-title":"Apremilast in benign chronic pemphigus (Hailey\u2013Hailey disease)","volume":"45","author":"Riquelme-McLoughlin","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"2023010808133853300_ced15377-bib-0033","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/ced.14173","article-title":"Successful treatment of refractory Hailey\u2013Hailey disease with apremilast","volume":"45","author":"Di Altobrando","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"2023010808133853300_ced15377-bib-0034","first-page":"727","article-title":"Combination of dermabrasion and apremilast for Hailey-Hailey disease","volume":"156","author":"Siliquini","year":"2021","journal-title":"Ital J Dermatol Venerol"},{"key":"2023010808133853300_ced15377-bib-0035","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/ijd.15953","article-title":"Apremilast in combination with botulinum toxin-A injection for recalcitrant Hailey-Hailey disease","volume":"61","author":"Anto\u00f1anzas","year":"2022","journal-title":"Int J Dermatol"},{"key":"2023010808133853300_ced15377-bib-0036","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2340\/00015555-2995","article-title":"A case of pityriasis rubra pilaris treated successfully with the phosphodiesterase-4 inhibitor apremilast","volume":"98","author":"Cho","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"2023010808133853300_ced15377-bib-0037","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamadermatol.2015.3405","article-title":"Treatment of refractory pityriasis rubra pilaris with novel phosphodiesterase 4 (PDE4) inhibitor apremilast","volume":"152","author":"Krase","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2023010808133853300_ced15377-bib-0038","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1203475417733464","article-title":"Successful treatment of refractory type 1 pityriasis rubra pilaris with apremilast","volume":"22","author":"Molina-Figuera","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"2023010808133853300_ced15377-bib-0039","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1684\/ejd.2017.3187","article-title":"A case of severe pityriasis rubra pilaris with a dramatic response to apremilast","volume":"28","author":"Pellonnet","year":"2018","journal-title":"Eur J Dermatol"},{"key":"2023010808133853300_ced15377-bib-0040","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13060","article-title":"Patient experiences with biologics and apremilast in pityriasis rubra pilaris: a patient survey","volume":"32","author":"Maloney","year":"2019","journal-title":"Dermatol Ther"},{"key":"2023010808133853300_ced15377-bib-0041","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jamadermatol.2019.2130","article-title":"Refractory generalized granuloma annulare treated with oral apremilast","volume":"155","author":"Bishnoi","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2023010808133853300_ced15377-bib-0042","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jdcr.2019.09.015","article-title":"Treatment of generalized granuloma annulare with apremilast: a report of 2 cases","volume":"5","author":"Blum","year":"2019","journal-title":"JAAD Case Rep"},{"key":"2023010808133853300_ced15377-bib-0043","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/ced.14806","article-title":"Generalized granuloma annulare successfully treated with apremilast: report of two cases and literature review","volume":"46","author":"Hansel","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2023010808133853300_ced15377-bib-0044","article-title":"Apremilast in the management of disseminated granuloma annulare","volume":"13","author":"Joshi","year":"2021","journal-title":"Cureus"},{"key":"2023010808133853300_ced15377-bib-0045","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1056\/NEJMc1901987","article-title":"Apremilast in treatment-refractory recurrent aphthous stomatitis","volume":"381","author":"Kolios","year":"2019","journal-title":"N Engl J Med"},{"key":"2023010808133853300_ced15377-bib-0046","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1097\/RHU.0000000000000843","article-title":"Complex aphthae treated with apremilast","volume":"26","author":"Gi\u00e1caman von der Weth","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"2023010808133853300_ced15377-bib-0047","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jdcr.2017.06.017","article-title":"Apremilast for treatment of recalcitrant aphthous stomatitis","volume":"3","author":"Schibler","year":"2017","journal-title":"JAAD Case Rep"},{"key":"2023010808133853300_ced15377-bib-0048","doi-asserted-by":"crossref","first-page":"adv00118","DOI":"10.2340\/00015555-3461","article-title":"Efficacy of apremilast in patients with prurigo nodularis: a proof-of-concept study","volume":"100","author":"Todberg","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2023010808133853300_ced15377-bib-0049","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.154","article-title":"Evaluation of apremilast in chronic pruritus of unknown origin: a proof-of-concept, phase 2a, open-label, single-arm clinical trial","volume":"3","author":"Clark","year":"2020","journal-title":"Health Sci Rep"},{"key":"2023010808133853300_ced15377-bib-0050","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jamadermatol.2013.10526","article-title":"An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study","volume":"150","author":"Thompson","year":"2014","journal-title":"JAMA Dermatol"},{"key":"2023010808133853300_ced15377-bib-0051","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archdermatol.2011.301","article-title":"Efficacy and safety of apremilast in chronic cutaneous sarcoidosis","volume":"148","author":"Baughman","year":"2012","journal-title":"Arch Dermatol"},{"key":"2023010808133853300_ced15377-bib-0052","first-page":"1224","article-title":"Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study","volume":"11","author":"De Souza","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"2023010808133853300_ced15377-bib-0053","doi-asserted-by":"crossref","first-page":"e917","DOI":"10.1111\/jdv.17585","article-title":"Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: a prospective single-centre pilot study","volume":"35","author":"Narang","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010808133853300_ced15377-bib-0054","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/bjd.18233","article-title":"Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases","volume":"182","author":"Narang","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023010808133853300_ced15377-bib-0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdcr.2021.11.009","article-title":"Apremilast as a treatment for morphea: a case series","volume":"19","author":"Koschitzky","year":"2022","journal-title":"JAAD Case Rep"},{"key":"2023010808133853300_ced15377-bib-0056","doi-asserted-by":"crossref","first-page":"adv00437","DOI":"10.2340\/00015555-3805","article-title":"Beneficial impact of apremilast on palmoplantar keratodermas","volume":"101","author":"Nakajima","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2023010808133853300_ced15377-bib-0057","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14345","article-title":"Apremilast in orofacial granulomatosis \u2013 a report of five cases","volume":"33","author":"Kaushik","year":"2020","journal-title":"Dermatol Ther"},{"key":"2023010808133853300_ced15377-bib-0058","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1203475419878162","article-title":"Recalcitrant seborrheic dermatitis successfully treated with apremilast","volume":"24","author":"Cohen","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"2023010808133853300_ced15377-bib-0059","doi-asserted-by":"crossref","DOI":"10.5070\/D3231033682","article-title":"Apremilast for treatment of recurrent erythema multiforme","volume":"23","author":"Chen","year":"2017","journal-title":"Dermatol Online J"},{"key":"2023010808133853300_ced15377-bib-0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjd.16897","article-title":"Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment","volume":"180","author":"Castela","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023010808133853300_ced15377-bib-0061","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.588315","article-title":"Case report: apremilast for therapy-resistant pemphigus vulgaris","volume":"11","author":"Meier","year":"2020","journal-title":"Front Immunol"},{"key":"2023010808133853300_ced15377-bib-0062","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jdcr.2020.08.019","article-title":"Successful treatment of refractory folliculitis decalvans with apremilast","volume":"6","author":"F\u00e4ssler","year":"2020","journal-title":"JAAD Case Rep"},{"key":"2023010808133853300_ced15377-bib-0063","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13809","article-title":"Successful use of apremilast as a steroid-sparing agent in chronic actinic dermatitis","volume":"33","author":"Kaushik","year":"2020","journal-title":"Dermatol Ther"},{"key":"2023010808133853300_ced15377-bib-0064","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/ajd.13253","article-title":"Improvement of recalcitrant Sneddon-Wilkinson disease with apremilast","volume":"61","author":"Magdaleno-Tapial","year":"2020","journal-title":"Australas J Dermatol"},{"key":"2023010808133853300_ced15377-bib-0065","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12879","article-title":"Chronic hand eczema and hepatogenic pruritus with good response to apremilast","volume":"32","author":"Navarro-Trivi\u00f1o","year":"2019","journal-title":"Dermatol Ther"},{"key":"2023010808133853300_ced15377-bib-0066","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bjd.16071","article-title":"Successful treatment of SAPHO syndrome with apremilast","volume":"179","author":"Adamo","year":"2018","journal-title":"Br J Dermatol"},{"key":"2023010808133853300_ced15377-bib-0067","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1097\/IOP.0000000000001047","article-title":"Apremilast use in a case of cicatricial ectropion secondary to severe lamellar ichthyosis","volume":"34","author":"Abboud","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2023010808133853300_ced15377-bib-0068","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdcr.2017.02.019","article-title":"Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum","volume":"3","author":"Laird","year":"2017","journal-title":"JAAD Case Rep"},{"key":"2023010808133853300_ced15377-bib-0069","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jdcr.2021.07.012","article-title":"Refractory erythema annulare centrifugum treated with apremilast","volume":"15","author":"Lee","year":"2021","journal-title":"JAAD Case Rep"},{"key":"2023010808133853300_ced15377-bib-0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jdcr.2021.08.031","article-title":"Treatment of a perforating dermatosis with apremilast","volume":"16","author":"McMichael","year":"2021","journal-title":"JAAD Case Rep"},{"key":"2023010808133853300_ced15377-bib-0071","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/ijt.ijt_59_19","article-title":"Apremilast in refractory alopecia areata","volume":"11","author":"Est\u00e9banez","year":"2019","journal-title":"Int J Trichol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ced.15377","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ced.15377","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/47\/12\/2136\/48531041\/ced2136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/47\/12\/2136\/48531041\/ced2136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T21:24:30Z","timestamp":1700947470000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/47\/12\/2136\/6966200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":71,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,1]]},"published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1111\/ced.15377","relation":{},"ISSN":["1365-2230","0307-6938"],"issn-type":[{"value":"1365-2230","type":"electronic"},{"value":"0307-6938","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"2022-08-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}